Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

Colossal Biosciences is in talks to raise new funding at a $20 billion to $30 billion valuation, according to Axios. The five-year-old startup, led by CEO Ben Lamm, has started generating revenue and expanded its de-extinction business. Colossal has also spun out several startups, including Breaking and Form Bio.